---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000013"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:41:13.596058+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech receives positive CHMP opinion for VYJUVEK in EU; EC decision expected Q2 2025

## Summary
- CHMP recommends EC approval of VYJUVEK for DEB wounds, including from birth, with option for at-home administration.
- Final EC decision anticipated in Q2 2025, applicable to EU member states plus Iceland, Norway, Liechtenstein.
- Positive opinion based on Phase 1/2 GEM-1 and Phase 3 GEM-3 data showing durable wound closure.
- Company expects first European launch in Germany around mid-2025, followed by France later in 2025.
- VYJUVEK previously approved by FDA in May 2023 for DEB patients aged 6 months and older in the U.S.

## SEC filing metadata
- accession: 0001711279-25-000013
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000013/0001711279-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000013/krys-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000013
- JSON: https://secwatch.observer/filing/0001711279-25-000013.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.